AZD1152 in Patients With Advanced Solid Malignancies-Study 3

This study has been terminated.
(Study is now terminated due to technical difficulties with administration of study drug in this patient population with this schedule)
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00497679
First received: July 5, 2007
Last updated: May 13, 2009
Last verified: May 2009

July 5, 2007
May 13, 2009
August 2006
Not Provided
Safety and Tolerability [ Time Frame: Assessed at each visit ]
Same as current
Complete list of historical versions of study NCT00497679 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics [ Time Frame: Assessed at predetermined timepoints after dose administration ]
  • Effect on biomarkers [ Time Frame: Assessed after treatment ]
  • Anti-tumor activity [ Time Frame: Assessed at the end of treatment ]
Same as current
Not Provided
Not Provided
 
AZD1152 in Patients With Advanced Solid Malignancies-Study 3
A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1152 Given as a Continuous 7-Day Intravenous Infusion in Patients With Advanced Solid Malignancies

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Solid Tumours
Drug: AZD1152
7-day continuous intravenous infusion
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
45
July 2007
Not Provided

Inclusion Criteria:

  • Histological or cytological confirmation of a solid, malignant tumour

Exclusion Criteria:

  • Participation in an investigational drug study within 21 days prior to entry or who have not recovered from the effects of an investigational study drug
  • Treatment with radiotherapy/chemotherapy with 4 weeks of first dose
  • Recent major surgery within 4 weeks prior to entry to the study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT00497679
D1531C00003, EudraCT: 2005-004244-31
No
Not Provided
AstraZeneca
Not Provided
Principal Investigator: David Kerr, MD University of Oxford
AstraZeneca
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP